Ezh2-Interacting Lncrnas Contribute to Gastric Tumorigenesis; a Review on the Mechanisms of Action Publisher Pubmed

Summary: Review explores EZH2-interacting lncRNAs in gastric cancer, highlighting their role in tumor progression and therapy potential. #GastricCancer #lncRNAs

Mohebbi H¹ ; Esbati R² ; Hamid RA³ ; Akhavanfar R⁴ ; Radi UK⁵ ; Siri G⁶ ; Yazdani O²
Source: Molecular Biology Reports Published:2024

Abstract

Gastric cancer (GC) remains one of the deadliest malignancies worldwide, demanding new targets to improve its diagnosis and treatment. Long non-coding RNAs (lncRNAs) are dysregulated through gastric tumorigenesis and play a significant role in GC progression and development. Recent studies have revealed that lncRNAs can interact with histone-modifying polycomb protein, enhance Zeste Homolog 2 (EZH2), and mediate its site-specific functioning. EZH2, which functions as an oncogene in GC, is the catalytic subunit of the PRC2 complex that induces H3K27 trimethylation and epigenetically represses gene expression. EZH2-interacting lncRNAs can recruit EZH2 to the promoter regions of various tumor suppressor genes and cause their transcriptional deactivation via histone methylation. The interactions between EZH2 and this lncRNA modulate different processes, such as cell cycle, cell proliferation and growth, migration, invasion, metastasis, and drug resistance, in vitro and in vivo GC models. Therefore, EZH2-interacting lncRNAs are exciting targets for developing novel targeted therapies for GC. Subsequently, this review aims to focus on the roles of these interactions in GC progression to understand the therapeutic value of EZH2-interacting lncRNAs further. © The Author(s), under exclusive licence to Springer Nature B.V. 2024.